# GLP‑1

Pfizer’s Monthly GLP‑1 Shows Promising Weight‑Loss Signal — A New Challenger in a Crowded Market

Pfizer’s long‑acting GLP‑1 candidate PF‑08653944 produced a 12.3% placebo‑adjusted mean weight loss at 28 weeks and sustained reductions after switching to monthly dosing, with mainly mild‑to‑moderate gastrointestinal side effects. The company has launched an ambitious phase 3 programme of ten trials and plans to advance full development in 2026, positioning itself to challenge incumbent GLP‑1 therapies if larger trials confirm efficacy and safety.

NeTe2026年2月3日 12:50

#Pfizer#GLP‑1#PF‑08653944

Blurred background view with focus on fuel pump display showing price and liters.

Business

Slimmer Passengers, Fatter Margins: How GLP‑1 Weight‑loss Drugs Could Trim Airline Fuel Bills

Jefferies forecasts that GLP‑1 weight‑loss drugs could cut U.S. major airlines’ fuel bills by up to $580 million annually as lighter passengers reduce aircraft payload. While direct fuel savings are small, fleet‑wide weight reductions can meaningfully boost margins, raising corporate and ethical questions about relying on medical trends for cost savings.

NeTe2026年1月20日 05:10

#GLP‑1#airlines#fuel costs